FMT to Convert Response to Immunotherapy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

FMT to Convert Response to Immunotherapy — Stella

Recruiting

Back to Melanoma Stage III trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Netherlands

Antoni van Leeuwenhoek, Amsterdam

Key details

Phase

Early testing / Safety & dosing

Sponsor

The Netherlands Cancer Institute

Enrollment target

~24 participants

Started

August 2022

Primary completion

August 2026

Age range

18 Years and older

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov